• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高度改善的铟-111-DOTA-胃泌素缀合物的代谢稳定性和药代动力学,用于胃泌素受体的靶向。

Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.

机构信息

Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.

出版信息

J Med Chem. 2011 Apr 28;54(8):2602-9. doi: 10.1021/jm101279a. Epub 2011 Apr 1.

DOI:10.1021/jm101279a
PMID:21456601
Abstract

The development of metabolically stable radiolabeled gastrin analogues with suitable pharmacokinetics is a topic of recent research activity. These imaging vectors are of interest because the gastrin/CCK2 receptor is highly overexpressed in different tumors such as medullary thyroid cancer, neuroendocrine tumors, and SCLC. The drawback of current targeting agents is either their metabolic instability or their high kidney uptake. We present the synthesis and in vitro and in vivo evaluation of 11 (111)In-labeled DOTA-conjugated peptides that differ by their spacer between the peptide and the chelate. We introduced uncharged but hydrophilic spacers such as oligoethyleneglycol, serine, and glutamine. The affinity of all radiopeptides was high with IC(50) values between 0.5 and 4.8 nM. The improvement of human serum stability is 500-fold within this series of compounds. In addition the kidney uptake could be lowered distinctly and the tumor-to-kidney ratio improved almost 60-fold if compared with radiotracers having charged spacers such as glutamic acid.

摘要

具有合适药代动力学的代谢稳定放射性标记胃泌素类似物的开发是近期研究活动的一个主题。这些成像载体很有意义,因为胃泌素/CCK2 受体在不同的肿瘤中高度过表达,如甲状腺髓样癌、神经内分泌肿瘤和小细胞肺癌。目前靶向剂的缺点是代谢不稳定或肾脏摄取高。我们介绍了 11(111)In 标记的 DOTA 缀合肽的合成及体外和体内评价,这些肽在肽和螯合剂之间的间隔有所不同。我们引入了不带电荷但亲水性的间隔物,如聚乙二醇、丝氨酸和谷氨酰胺。所有放射性肽的亲和力都很高,IC(50)值在 0.5 和 4.8 nM 之间。在这一系列化合物中,人血清稳定性提高了 500 倍。此外,如果与带电荷间隔物(如谷氨酸)的放射性示踪剂相比,肾脏摄取可明显降低,肿瘤与肾脏的比值可提高近 60 倍。

相似文献

1
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.高度改善的铟-111-DOTA-胃泌素缀合物的代谢稳定性和药代动力学,用于胃泌素受体的靶向。
J Med Chem. 2011 Apr 28;54(8):2602-9. doi: 10.1021/jm101279a. Epub 2011 Apr 1.
2
Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.氨基酸间隔臂的立体化学决定了用于靶向CCK2/胃泌素受体的(111)铟-DOTA-胃泌素类似物的药代动力学。
Bioconjug Chem. 2015 Jun 17;26(6):1113-9. doi: 10.1021/acs.bioconjchem.5b00187. Epub 2015 May 20.
3
In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.三种用于胆囊收缩素受体成像的 68Ga-和 111In 标记肽的体外和体内特性。
Mol Imaging. 2012 Sep-Oct;11(5):401-7.
4
PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.与DOTA、NOTA和NODAGA共轭并用(64)Cu、(68)Ga和(111)In标记的放射性标记小分子胃泌素类似物的正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)成像
Mol Pharm. 2014 Nov 3;11(11):3930-7. doi: 10.1021/mp500283k. Epub 2014 Jul 11.
5
Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.用于靶向 CCK2 受体阳性肿瘤的稳定(111)标记 sCCK8 类似物:合成与评价。
Bioconjug Chem. 2010 Apr 21;21(4):663-70. doi: 10.1021/bc900465y.
6
Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.比较 12 个 DOTA 偶联和 ¹¹¹In 标记的 CCK2/胃泌素受体结合肽的结合和内化特性:COST 行动 BM0607 下的合作项目。
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1417-25. doi: 10.1007/s00259-011-1816-y. Epub 2011 Apr 20.
7
Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.胆囊收缩素-B/胃泌素受体结合肽:临床前开发及其诊断和治疗潜力评估
Clin Cancer Res. 1999 Oct;5(10 Suppl):3124s-3138s.
8
Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.用于靶向表达胆囊收缩素B/胃泌素受体肿瘤的放射性标记肽。
J Nucl Med. 1999 Jun;40(6):1029-44.
9
Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides.125I 标记的胃泌素/胆囊收缩素 2 受体靶向肽的比较生物分布。
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1410-6. doi: 10.1007/s00259-011-1806-0. Epub 2011 Apr 2.
10
Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.基于胃泌素和胆囊收缩素肽的放射性药物:体内和体外比较。
J Pept Sci. 2011 May;17(5):405-12. doi: 10.1002/psc.1327. Epub 2011 Feb 24.

引用本文的文献

1
Precision peptide theranostics: developing - to -terminus optimized theranostics targeting cholecystokinin-2 receptor.精准肽治疗学:开发针对胆囊收缩素-2 受体的从 N 端到 C 端优化的治疗学方法。
Theranostics. 2024 Feb 24;14(5):1815-1828. doi: 10.7150/thno.89701. eCollection 2024.
2
Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.通过基于放射杂交的小胃泌素类似物中优化的连接子序列,显著降低肾脏中的活性保留。
EJNMMI Res. 2024 Mar 2;14(1):23. doi: 10.1186/s13550-024-01087-5.
3
Effect of -Terminal Peptide Modifications on In Vitro and In Vivo Properties of Lu-Labeled Peptide Analogs Targeting CCK2R.
C末端肽修饰对靶向CCK2R的镥标记肽类似物体外和体内性质的影响。
Pharmaceutics. 2023 Feb 28;15(3):796. doi: 10.3390/pharmaceutics15030796.
4
Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCKR Cancer Theranostic Agents: A Preclinical Study.标记有三价放射性金属的非肽类Z360类似物作为抗CCKR癌症诊疗剂的临床前研究。
Pharmaceutics. 2022 Mar 18;14(3):666. doi: 10.3390/pharmaceutics14030666.
5
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.胆囊收缩素-2受体靶向放射性药物的临床前开发与临床转化进展
Cancers (Basel). 2021 Nov 18;13(22):5776. doi: 10.3390/cancers13225776.
6
Radiopharmaceutical Formulation and Preclinical Testing of Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.用于首个探索性临床试验监管批准的镓标记DOTA-MGS5的放射性药物制剂及临床前测试
Pharmaceuticals (Basel). 2021 Jun 16;14(6):575. doi: 10.3390/ph14060575.
7
Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements the Inclusion of Proline into the Peptide Sequence.线性 Minigastrin 类似物的稳定化策略:进一步改进在肽序列中引入脯氨酸。
J Med Chem. 2020 Dec 10;63(23):14668-14679. doi: 10.1021/acs.jmedchem.0c01233. Epub 2020 Nov 23.
8
Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.新型 CCK2R 靶向肽类似物的体外和体内初步评价,该类似物用镥-177 标记。
Molecules. 2020 Oct 8;25(19):4585. doi: 10.3390/molecules25194585.
9
Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [Lu]Lu-PP-F11N.mTORC1 的药理学抑制可增加放射性标记的 minigastrin 类似物 [Lu]Lu-PP-F11N 对 CCKBR 特异性肿瘤摄取。
Theranostics. 2020 Aug 29;10(24):10861-10873. doi: 10.7150/thno.45440. eCollection 2020.
10
Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.胆囊收缩素-2 受体放射性肽靶向:现状与未来方向。
Curr Med Chem. 2020;27(41):7112-7132. doi: 10.2174/0929867327666200625143035.